Ayisha Sharma

Novo Nordisk disclosed several key updates from its cardiometabolic and hematology pipelines Wednesday as the drugmaker revealed its third-quarter profits edged out expectations.

Arcus Biosciences unveiled data from a terminated late-stage study of its TIGIT and PD-1 drug combo that it says supports its decision to take the …

Genmab is culling a trio of early oncology assets to focus on upcoming milestones for its late-stage programs that include an ADC from its purchase …

Athira Pharma has shelved a daily drug for Alzheimer's after a mid-stage flop, instead shifting its focus to an oral candidate with the same target …

In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating capacity ...

A Danish company is spending $145 million upfront for certain rights to the first-ever needle-free adrenaline nasal spray for severe allergic reactions, unlocking sales potential …

Bayer reiterated its plans to ride out the generic-driven sales decline of its thrombosis drug Xarelto, as the company's shares plummeted to a record low …

Syros Pharmaceuticals' share price nosedived after its last drug candidate flunked a trial in hematological malignancies for the second time in recent months.

GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in 2025, targeting $3 billion peak sales and competition with Johnson & Johnson's Darzalex.

Adaptimmune is slashing its headcount as part of a broader company restructuring aimed at saving $300 million over the next few years through 2028. …